Pipeline
| Pipeline | Indication | Major targets/MoA | Development Phase |
|---|---|---|---|
| MT101 | Parkinson’s disease | Nurr1 & Proteasome activation (α-syn clearance) |
Phase 2a IND clearance (US FDA) |
| MT9801 (DA-9801, NB-01) |
Diabetic neuropathy | NGF-TrkA & I2A-β-endorphin activation |
Phase 2 completed (US FDA) |
| MT102 | Inflammatory bowel disease | AhR activation & NLRP3 inflammasome inhibition |
Phase 1 completed (KR MFDS) |
| MT104 | Mild cognitive impairment | Phosphorylated tau inhibition &PSD95, BDNF activation |
Human trial(PoC) completed, Preparing for approval (KR MFDS) |
| MT103 | Type 2 diabetes/MASH | Improvement of insulin resistance (Target identification research in progress) |
Candidate |
| MT106 | Virus-mediated diseases | Inhibition of herpes/RNA virus replication and reactivation | Candidate |
